These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8835058)

  • 21. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinically manifest liver lesions during use of simvastatin].
    Koornstra JJ; Ottervanger JP; Fehmers MC; Stricker BH
    Ned Tijdschr Geneeskd; 1996 Apr; 140(15):846-8. PubMed ID: 8668280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].
    Meier C; Stey C; Brack T; Maggiorini M; Risti B; Krähenbühl S
    Schweiz Med Wochenschr; 1995 Jul; 125(27-28):1342-6. PubMed ID: 7624744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
    Tobert JA
    Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    McMillan K
    Am J Health Syst Pharm; 1996 Sep; 53(18):2206-14. PubMed ID: 8879334
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute cholestatic hepatitis during simvastatin administration.
    Ballaré M; Campanini M; Catania E; Bordin G; Zaccala G; Monteverde A
    Recenti Prog Med; 1991 Apr; 82(4):233-5. PubMed ID: 1857844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Side effects of HMG CoA reductase inhibitors.
    Ahmad S
    Heart Dis Stroke; 1993; 2(3):262-3. PubMed ID: 8137036
    [No Abstract]   [Full Text] [Related]  

  • 31. [Simvastatin in the treatment of hypercholesterolemia].
    Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
    Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
    Keller RK; Zhao Z; Chambers C; Ness GC
    Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
    Drown DJ
    Prog Cardiovasc Nurs; 1996; 11(2):38-9. PubMed ID: 8718962
    [No Abstract]   [Full Text] [Related]  

  • 34. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.
    Choi JW; Jung SE
    J Pharmacol Exp Ther; 1999 Apr; 289(1):572-9. PubMed ID: 10087052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psychiatric disorders with use of simvastatin].
    Duits N; Bos FM
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1312-5. PubMed ID: 8345888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reductase inhibitor therapy of hypercholesterolemia.
    Kreisberg RA
    Trans Am Clin Climatol Assoc; 1991; 102():153-63; discussion 163-5. PubMed ID: 2130558
    [No Abstract]   [Full Text] [Related]  

  • 40. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.